SurVaxM

MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the Phase 2b SURVIVE trial of SurVaxM, an investigational cancer vaccine, in patients with newly diagnosed glioblastoma. Glioblastoma is an aggressive brain cancer with few effective treatments, so outcomes from this trial are drawing attention from oncology researchers and patients awaiting new therapeutic options.